Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Obsessive-Compulsive Disorder - Overview Obsessive-Compulsive Disorder - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Obsessive-Compulsive Disorder - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Obsessive-Compulsive Disorder - Companies Involved in Therapeutics Development Addex Therapeutics Ltd Amorsa Therapeutics Inc Biohaven Pharmaceutical Holding Company Ltd Omeros Corp Obsessive-Compulsive Disorder - Drug Profiles ADX-88178 - Drug Profile Product Description Mechanism Of Action R&D Progress OMS-527 - Drug Profile Product Description Mechanism Of Action R&D Progress PECS-101 - Drug Profile Product Description Mechanism Of Action R&D Progress psilocybin - Drug Profile Product Description Mechanism Of Action R&D Progress SERx-480 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Antagonize GRIN2B for Autism and Obsessive Compulsive Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Target NMDA Receptor for Obsessive Compulsive Disorder - Drug Profile Product Description Mechanism Of Action R&D Progress troriluzole hydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress Obsessive-Compulsive Disorder - Dormant Projects Obsessive-Compulsive Disorder - Discontinued Products Obsessive-Compulsive Disorder - Product Development Milestones Featured News & Press Releases Mar 19, 2013: Omeros Elucidates Mechanism Of PDE7 Inhibitors In Addiction Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development for Obsessive-Compulsive Disorder, H1 2019 Number of Products under Development by Companies, H1 2019 Number of Products under Development by Universities/Institutes, H1 2019 Products under Development by Companies, H1 2019 Products under Development by Universities/Institutes, H1 2019 Number of Products by Stage and Target, H1 2019 Number of Products by Stage and Mechanism of Action, H1 2019 Number of Products by Stage and Route of Administration, H1 2019 Number of Products by Stage and Molecule Type, H1 2019 Obsessive-Compulsive Disorder - Pipeline by Addex Therapeutics Ltd, H1 2019 Obsessive-Compulsive Disorder - Pipeline by Amorsa Therapeutics Inc, H1 2019 Obsessive-Compulsive Disorder - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H1 2019 Obsessive-Compulsive Disorder - Pipeline by Omeros Corp, H1 2019 Obsessive-Compulsive Disorder - Dormant Projects, H1 2019 Obsessive-Compulsive Disorder - Discontinued Products, H1 2019List of Figures Number of Products under Development for Obsessive-Compulsive Disorder, H1 2019 Number of Products under Development by Companies, H1 2019 Number of Products by Targets, H1 2019 Number of Products by Stage and Targets, H1 2019 Number of Products by Mechanism of Actions, H1 2019 Number of Products by Stage and Mechanism of Actions, H1 2019 Number of Products by Stage and Routes of Administration, H1 2019 Number of Products by Stage and Molecule Types, H1 2019

Addex Therapeutics Ltd Amorsa Therapeutics Inc Biohaven Pharmaceutical Holding Company Ltd Omeros Corp